Improved Medication Adherence with the Use of Extended-Release Tacrolimus in Liver Transplant Recipients: A Pilot Randomized Controlled Trial

Table 2

PROMIS-29 scores, baseline, and mean throughout the study.

		TAC-ER (n = 9)	TAC-IR (n = 16)	value
Fatigue, mean (SD)	Baseline	51.1 (14.2)	47.4 (9.1)	0.44
	Week 4-month 9	55.7 (9.7)	51.4 (7.7)	0.23
Sleep disturbance, mean (SD)	Baseline	54.3 (4.2)	51.2 (3.6)	0.069
	Week 4-month 9	52.4 (2.4)	52.4 (1.7)	0.99
Anxiety, mean (SD)	Baseline	52.2 (12.1)	47.3 (7.2)	0.23
	Week 4-month 9	56.2 (11.2)	50.1 (7.8)	0.12
Depression, mean (SD)	Baseline	50.4 (10.3)	45.6 (5.8)	0.16
	Week 4-month 9	54.1 (10.5)	48.9 (5.9)	0.13
Physical function, mean (SD)	Baseline	29.1 (7.0)	28.3 (5.6)	0.77
	Week 4-month 9	28.6 (8.0)	29.9 (6.6)	0.67
Social roles, mean (SD)	Baseline	41.4 (9.2)	27.0 (8.3)	0.24
	Week 4-month 9	41.7 (9.2)	38.6 (7.5)	0.38
Pain interference, mean (SD)	Baseline	52.9 (11.8)	51.9 (10.7)	0.84
	Week 4-month 9	50.6 (10.3)	51.5 (10.4)	0.83
Pain intensity, mean (SD)	Baseline	3.5 (3.9)	2.9 (3.9)	0.70
	Week 4-month 9	3.1 (3.2)	3.2 (2.8)	0.92